

Mirvaso - (EQ 0.33% BASE; Gel, Topical)

| | | | |
|------------------------------|--|-----------------------------|---------------------|
| Generic Name | Brimonidine | Innovator | Galderma |
| Dosage | EQ 0.33% BASE; Gel, Topical | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | None |
| Final Approvals | Less Than 5 | Generic Launches | Less Than 5 |
| Indication | Indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.